Navrogen Inc. is a biopharmaceutical company focused on the targeted treatment of cancer. Navrogen is currently working on enhancing the immune system to fight cancer by removing the effect of factors produced or induced by tumor cells which inhibit the cancer-fighting humoral immune system.
Location: United States, Pennsylvania, Thornbury Township
Employees: 1-10
Total raised: $6.2M
Founded date: 2017
Investors 1
| Date | Name | Website |
| - | Ben Frankl... | sep.benfra... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 10.08.2021 | Seed | $3M | - |
| 17.09.2019 | - | $3.2M | - |
Mentions in press and media 11
| Date | Title | Description |
| 08.09.2025 | Navrogen Awarded Nat'l Cancer Institute Grant to Develop Antagonists to Treat Humoral Immuno-Oncology Positive Cancers | Navrogen Awarded National Cancer Institute Grant to Develop Antagonists to Treat Humoral Immuno-Oncology (HIO) Positive Cancers CHEYNEY, PA, UNITED STATES, September 8, 2025 /EINPresswire.com/ -- Cheyney, PA, September 8, 2025 - Navrogen, I... |
| 05.05.2025 | Navrogen Announces Publication on the CA125-Refractory NAV-006 Ab Treatment of Immunosuppressed Follicular Lymphoma | Navrogen Inc Announces Publication on the CA125-Refractory NAV-006 Antibody for the Treatment of Immunosuppressed Follicular Lymphoma CHEYNEY, PA, UNITED STATES, May 5, 2025 /EINPresswire.com/ -- Cheyney, PA, May, 5 2025 - Navrogen, Inc., a... |
| 26.03.2025 | Navrogen Announces Publication and Presentation at the AACR Annual Meeting of a Novel Antibody Engineering Platform | Navrogen Inc Announces Publication of a Novel Antibody Engineering Platform CHEYNEY, PA, UNITED STATES, March 26, 2025 /EINPresswire.com/ -- Navrogen, Inc., a biopharmaceutical company specialized in developing antibody-based therapies for ... |
| 01.05.2023 | Money Moves: Motobyo launched two crowdfunding campaigns to raise $4M | Money Moves is a column where we chart the funding raises of tech companies across the region. Have a tip? Email us at philly@technical.ly. Motobyo seeks $4 million raise with crowdfunding campaigns Motobyo, the Horsham-based startup with a... |
| 27.03.2023 | Navrogen and National Cancer Institute Establish Collaboration Study Impact Immunosuppressive Factor CA125 on Rituximab | Navrogen and the National Cancer Institute Establish Collaboration to Study the Impact of Immunosuppressive Factor CA125 on Rituximab Effectiveness CHEYNEY, PA, UNITED STATES, March 27, 2023/EINPresswire.com/ -- Cheyney, PA, March 27th, 202... |
| 18.10.2021 | Ben Franklin Approved $2.1M in 12 Early Stage Companies | |
| 10.08.2021 | Navrogen Raises $3.0M in Seed Funding | Navrogen, Inc., a Cheyney, Pa.-based preclinical biotechnology company, raised $3.0M in equity financing. The financing was led by Tellus BioVentures along with existing investors. As part of the financing, Lonnie Moulder, Managing Member o... |
| 09.08.2021 | Navrogen Closes $3.0M Seed Financing To Advance Its Preclinical Pipeline Targeting Humoral Immunosuppressed Cancers And Immune-Related Disorders | CHEYNEY, Pa., Aug. 9, 2021 /PRNewswire/ -- Navrogen, Inc., a privately held preclinical biotechnology company, announced today that it has raised $3.0M from an equity financing to support its Humoral Immuno-Oncology (HIO) discovery platform... |
| 17.09.2019 | Navrogen Closes $3.2M Funding | Navrogen, Inc., a Philadelphia, PA-based biotechnology company, raised $3.2M in convertible note financing. The round was led by Ben Franklin Technology Partners of South Eastern Pennsylvania and a number of private investors. The company w... |
| 17.09.2019 | Navrogen Announces The Closing Of $3.2M Funding | Navrogen, Inc. announced today that it has raised $3.2M in convertible note financing to support its operations, Humoral Immuno-Oncology (HIO) discovery platform and preclinical therapeutic pipeline activities. The financing was led by Ben ... |
Show more